Clinical trialPhase 1Completed

Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma

An Open-label Phase 1b Study to Evaluate the Safety and Efficacy of CCX872-B in Patients With Pancreatic Adenocarcinoma

NCT02345408 ↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome: Finished, no results posted
Phase: Phase 1
Status: Completed
Study type: Interventional
Start: February 2015
Expected end: 6 May 2020
Enrollment: 54 participants
Sites: 6
Primary outcomes: progression-free survival; subject incidence of Grade 3 or 4 adverse events
Sponsor: Industry
Results posted: No
Last update: 27 February 2025

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is an open-label phase 1-b study to evaluate the safety and efficacy of CCX872-B in patients with pancreatic adenocarcinoma also receiving FOLFIRINOX chemotherapy.

Detailed description public domain (ClinicalTrials.gov)

Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.